MRSN

Mersana Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

consensus rating "Buy"

Revenue Beats Expectation

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MRSN

Mersana Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing antibody drug conjugates to cure various cancers

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

06/28/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

102

Fiscal Year Ends

12-31

Website

www.mersana.com

Security Type

Common stock

Office address

840 Memorial Drive, Cambridge, MA 02139

Business

Introduction

Mersana Therapeutics, Inc., was incorporated in Delaware in February 2002 under the name Nanopharma Corp. In November 2005, they changed their name to Mersana Therapeutics, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, or ADCs, that provide clinically meaningful benefits to cancer patients with significant unmet needs. The company leverages 20 years of industry learning in the ADC field to develop proprietary technologies that enable designed ADCs to have better efficacy, safety and tolerability relative to existing ADC therapies. In addition, the Company entered into a strategic partnership with Takeda Pharmaceutical Company Limited or Takeda, whereby the Company acquired the rights to the XMT-1522 outside the United States and Canada. The company also has strategic R&D partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates for a limited number of targets selected by partners based on their Dolaflexin platform.

Company Financials

EPS

MRSN has released its 2024 Q4 earnings. EPS was reported at -0.11, versus the expected -0.17, beating expectations. The chart below visualizes how MRSN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MRSN has released its 2024 Q4 earnings report, with revenue of 16.36M, reflecting a YoY change of 52.89%, and net profit of -14.12M, showing a YoY change of 27.77%. The Sankey diagram below clearly presents MRSN’s revenue sources and cost distribution.